Capecitabine
| Parameter | Specification |
|---|---|
| Product Name | Capecitabine |
| CAS Number | 154361-50-9 |
| Molecular Formula | C15H22FN3O6 |
| Molecular Weight | 359.35 g/mol |
| Appearance | White to off-white crystalline powder |
| Assay (HPLC) | 98.0% - 102.0% |
| Solubility | Soluble in water, methanol; slightly soluble in ethanol |
| Package | 25 kg net weight in fiber drums with double polyethylene bags |
Need help? Contact our team

Synonyms: Capecitabine, 154361-50-9, Xeloda, Ro 09-1978, 5′-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
Capecitabine has become a cornerstone in oral chemotherapy regimens, drawing consistent demand from generic drug manufacturers and research organizations worldwide. Its ability to be administered orally, unlike many traditional chemotherapeutics, has made it a preferred choice for both clinical use and formulation development. As patents expire and healthcare systems seek cost-effective alternatives, the need for high-quality API from reliable suppliers continues to grow.
Chemically, capecitabine is a fluoropyrimidine carbamate prodrug of 5-fluorouracil (5-FU). It is synthesized through a multi-step process that introduces a pentyloxycarbonyl group to the cytidine ring, enhancing oral bioavailability. The compound is manufactured under strict conditions to ensure consistent purity and performance, with final crystallization yielding a white to off-white powder that meets pharmacopeial standards.
Our capecitabine is produced under GMP conditions and standardized to 98.0% – 102.0% assay by HPLC. It is available in bulk quantities, supported by comprehensive documentation and fast turnaround, making it suitable for generic formulation, clinical research, and reference standard applications.
Capecitabine is a synthetic nucleoside analog that acts as a prodrug. After oral administration, it undergoes enzymatic conversion to 5-FU, which inhibits thymidylate synthase and disrupts DNA synthesis. This targeted activation within tumor tissues reduces systemic toxicity compared to intravenous 5-FU.
The API is characterized by its high purity and consistent particle size distribution, critical for reproducible tablet manufacturing. Each batch is tested for identity, assay, and impurity profile to ensure compliance with USP/EP monographs.
| Test Item | Specification |
|---|---|
| Identification | IR, HPLC retention time conforms to standard |
| Loss on Drying | ≤ 0.5% |
| Heavy Metals | ≤ 20 ppm |
| Organic Impurities | Meets USP/EP requirements |
| Microbial Limits | Total aerobic count ≤ 1000 CFU/g; Yeast & Mold ≤ 100 CFU/g; E. coli absent |
| Residual Solvents | Complies with ICH Q3C guidelines |
Our MOQ is 1 kg. For larger quantities, we offer competitive pricing and flexible shipping terms.
For stock items, delivery time is 3-5 business days after order confirmation.
Yes, we provide a COA for each batch and can supply samples for quality evaluation. Please contact us for details.
send us your specification for a quotation.
Room,5-0203, Unit 5, Beiyuanmen Street,Xi'an,Shaanxi,China